Vertex Pharmaceuticals Inc. stock rises Friday, still underperforms market
The stock's rise snapped a four-day losing streak.
Vertex Pharma wins EU backing to expand label for Kaftrio cystic fibrosis drug
Vertex Pharmaceuticals (VRTX) stock in focus as company secures EU backing to expand label for its cystic fibrosis therapy ...
Analysts Offer Insights on Healthcare Companies: Alphatec Holdings (ATEC), Vertex Pharmaceuticals (VRTX) and Viridian Therapeutics (VRDN)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alphatec Holdings (ATEC – Research Report), Vertex ...
Vertex Pharmaceuticals upgraded to Buy from Hold at Erste Group
Erste Group upgraded Vertex Pharmaceuticals (VRTX) to Buy from Hold. The firm expects the company to “develop positively in the coming quarters ...
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 15 Years
Vertex Pharmaceuticals VRTX has outperformed the market over the past 15 years by 5.86% on an annualized basis producing an average annual return of 17.7%. Currently, Vertex Pharmaceuticals has a ...
Vertex Pharmaceuticals Incorporated (VRTX): Among Renaissance Technologies Portfolio’s Top Stock Picks
We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...
Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Raised to $408.00
Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its price target upped by Royal Bank of Canada from $407.00 to $408.00 ...
Brokers Offer Predictions for VRTX FY2025 Earnings
Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Vertex Pharmaceuticals in a research note issued to ...
2 Healthcare Stocks That Tumbled in 2024...but Could See an Impressive Comeback in 2025
In a phase 2 study, the company's medication suzetrigine barely performed better than a placebo in treating painful ...
Wall Street Journal16d
Vertex Pharmaceuticals Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...